Replies to post #121656 on Anavex Life Sciences Corp (AVXL)

[polarbear77]

"What would be worthy of all the silence?" you asked.

Great question.

Generally, would it be overly surprising if yet another small biotech struggled to achieve positive exploratory efficacy in a CNS disease trial?

Historically speaking, no. However in the case of Anavex it WOULD seem somewhat surprising if we found that this data quiet period related to confusing/ambiguous/poor 15/18/21 month extension results (surprising for reasons I've outlined already too many times).

So IF efficacy is instead promising and materially better than current SOC, then that opens the door to many POSITIVE potential answers to your "what would be worthy of all the silence?" question.

In my OPINION the signs are plentiful to argue that Anavex seemingly has positive efficacy results in hand to date.

When can/will they remove some of the MYSTERY for the market? Release updated pk/pd data as promised in the quarterly report..?

For some reason they don't seem to be in a big hurry; is that another positive sign in-and-of-itself (lack of desperation)?

GLTAL. Everyone please DYODD.